Portfolio
KeyMed Biosciences(2162.HK)
Macromolecular drug R&D platform, with its focus on oncology and autoimmune diseases
China
InventisBio
Small molecule drug R&D platform, with its focus on oncology and metabolic diseases
China
Micot
Peptide and protein drug R&D platform, with its focus on cardiovascular/cerebrovascular diseases, metabolic diseases, and pain related drugs
China
Vedanta
Bacterial innovative therapy R&D platform, with its focus on intestinal microenvironment
America
4B Technologies
Macromolecular drug R&D platform, with its focus on glaucoma, obesity, premature ovarian failure, ALS and NMO
China
WellGene
Gene therapy R&D platform, with its focus on oncology (oncolytic virus) and non-oncology (neurodegenerative diseases, genetic diseases, and blood diseases)
China
Cellestia
Novel gene transcription factor inhibitor R&D platform, with its focus on oncology
Switzerland
Angiex
Antibody-based therapeutics R&D platform, with its focus on TM4SF1 (Transmembrane-4 L Six Family member 1)
America
JURA
Innovative third generation CAR-T therapy R&D platform, with its focus on autoimmune diseases
America
Tavotek
Innovative macromolecular biological drug R&D platform, with its focus on treatment for oncology and autoimmune diseases
China
iRegene
iRegene is a globally leading biotech specializing in induced pluripotent stem cell (iPSC) therapies. Leveraging its proprietary "AI + chemical induction" platform, the company has pioneered chemically induced differentiation and regulatory, enabling the development of universal iPSC cell products with significant cost advantages. iRegene's flagship pipeline which focuses on Parkinson's Disease has completed Phase I clinical trials with compelling safety and efficacy data. It is positioned to become a Best-in-Class (BIC) therapy for mid-to-late stage Parkinson's disease.
China
Degron Therapeutics
Degron Therapeutics is a leading drug discovery platform company focusing on molecular glue degraders . The company has built a rapidly expanding compound library featuring novel and diverse scaffold structures, coupled with a robust drug screening and validation system. The company is dedicated to developing innovative molecular glue degraders that target previously undruggable disease targets
China
Concord Medical
Private cancer diagnosis/treatment chain hospital group in Beijing, Shanghai, Guangzhou
China
CH Biomedical
Magnetic left ventricular assist device (LVAD) R&D company, has developed the world's smallest full magnetic levitation artificial heart CH-VAD
China